



**CURRICULUM VITAE**

**Robert S. Lee, MD**

**Joined Los Alamitos Cardiovascular in 2013 | Partner since 2015**

5300 Katella Avenue, Los Alamitos, CA 90720

p: (562) 430-7533 | f: (562) 430-8055 | website: [www.losalcardio.com](http://www.losalcardio.com)

<b>Specialties:</b>	<b>Cardiology, Nuclear Cardiology, Echocardiography and Interventional Cardiology</b>
<b>Board Certifications:</b>	<ul style="list-style-type: none"> <li>• <b>Certified in Interventional Cardiology</b> American Board of Internal Medicine 2013 (Expires 2023)</li> <li>• <b>Certified in Cardiovascular Disease</b> American Board of Internal Medicine 2012 (Expires 2022)</li> <li>• <b>Diplomate, Echocardiography</b> National Board of Echocardiography 2011 (Expires 2021)</li> <li>• <b>Diplomate, Nuclear Cardiology</b> Certification Board of Nuclear Cardiology 2010 (Expires 2020)</li> <li>• <b>Certified in Internal Medicine</b> American Board of Internal Medicine 2008 (Expires 2018)</li> <li>• <b>Drug Enforcement Administration (DEA) Certificate</b> 2006 (Expires 2018)</li> <li>• <b>California State Licensure</b> Medical Board of California 2006 (Expires 2018)</li> </ul>
<b>Research Experience:</b>	<ul style="list-style-type: none"> <li>• <b>GALACTIC-HF:</b> Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction. Sub-Investigator   2017 Sponsor: Amgen NCT02929329: <a href="https://clinicaltrials.gov/ct2/show/NCT02929329">https://clinicaltrials.gov/ct2/show/NCT02929329</a></li> </ul>

- **PROVE-HF:** A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.  
 Sub-Investigator | 2017  
 Sponsor: Novartis  
 NCT02887183: <https://clinicaltrials.gov/ct2/show/NCT02887183>
- **Barostim Therapy for Heart Failure (BeAT-HF):** The Barostim Neo - Baroreflex Activation Therapy for Heart Failure is a prospective, randomized trial in subjects with reduced ejection fraction heart failure.  
 Sub-Investigator | 2016 – Present  
 Sponsor: CVRx, Inc.  
 NCT02627196: <https://clinicaltrials.gov/show/NCT02627196>
- **MLHFQ Study:** Evaluate and establish content validity of the Minnesota Living with Heart Failure Questionnaire (MLHFQ) in patients with Symptomatic Hypertrophic Cardiomyopathy.  
 Sub-Investigator | 2016  
 Sponsor: Gilead/ICON
- **THEMIS- A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus (THEMIS):** A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study).  
 Sub-Investigator | 2015 – Present  
 Sponsor: AstraZeneca  
 NCT01991795: <https://clinicaltrials.gov/show/NCT01991795>
- Retrospective Medical Records Review of Participants Interviewed for Study M-12347 (Concept Elicitation Focus Groups and Cognitive Interviews to Develop a New Patient Reported Outcome Instrument in Chronic Heart Failure).  
 Sub-Investigator | 2015  
 Sponsor: Amgen, Evidera
- **DECLARE-TIMI 58 Dapagliflozin Effect on CardiovascuLAR Events:** A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes.  
 Sub-Investigator | 2013 – Present  
 Sponsor: AstraZeneca

NCT01730534 | <http://clinicaltrials.gov/ct2/show/NCT01730534>

- **ODYSSEY EFC11570:** A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome  
Sub-Investigator | 2013 – Present  
Sponsor: Sanofi  
NCT01663402 | <http://clinicaltrials.gov/ct2/show/NCT01663402>
- **SILVER-AMI Risk Stratification in Older Persons with Acute Myocardial Infarction.**  
Sub-Investigator | 2013 – 2017  
Sponsor: Yale University School of Medicine/NIH  
NCT01755052 | <http://clinicaltrials.gov/ct2/show/NCT01755052>
- **Cardiovascular Inflammation Reduction Trial (CIRT):** Event Driven Trial of weekly Low-Dose Methotrexate in prevention of recurrent cardiovascular events among stable post myocardial infarction patients with Type II Diabetes or Metabolic Syndrome.  
Sub-Investigator | 2013– Present  
Sponsor: Center for Cardiovascular Disease Prevention Brigham and Women’s Hospital/National Heart Lung and Blood Institute  
NCT01594333 | <http://clinicaltrials.gov/ct2/show/NCT01594333>
- **The “BRIDGE” Trial (1U01HL08675501A1):** Bridging Anticoagulation in Patients Who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery.  
Sub-Investigator | 2012 – 2015  
Sponsor: National Institutes of Health (NIH)-National Heart, Lung and Blood Institute (NHLBI)  
NCT00786474 | <http://clinicaltrials.gov/ct2/show/NCT00786474>
- **GLORIA-AF 1160.129:** Global Registry on Long-Term Oral Anti-thrombotic Treatment in Patients with Atrial Fibrillation Phase II-III.  
Sub-Investigator | 2012 – Present  
Sponsor: Boehringer Ingelheim  
NCT01468701 | <http://clinicaltrials.gov/ct2/show/NCT01468701>
- **ORBIT-AF I and II:** Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.  
Sub-Investigator | 2010 – Present  
Sponsor: Janssen Scientific Affairs, LLC  
Collaborator: Duke Clinical Research

	<p>NCT01165710   <a href="http://clinicaltrials.gov/ct2/show/NCT01165710">http://clinicaltrials.gov/ct2/show/NCT01165710</a>  NCT01701817   <a href="http://clinicaltrials.gov/ct2/show/NCT01701817">http://clinicaltrials.gov/ct2/show/NCT01701817</a></p> <ul style="list-style-type: none"> <li> <p><b>ENGAGE:</b> Phase III, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus Warfarin in subjects with Atrial Fibrillation - Effective Anticoagulation with Xa next Generation in Atrial Fibrillation (ENGAGE - AF TIMI - 48).  Sub-Investigator   2013 – 2015  Sponsor: Daiichi Sankyo Pharma Development  NCT00781391   <a href="http://clinicaltrials.gov/ct2/show/record/NCT00781391">http://clinicaltrials.gov/ct2/show/record/NCT00781391</a></p> </li> <li> <p><b>Harbor-UCLA, Division of Cardiology: Clinical research involving the management and outcomes of patients with acute coronary syndromes in the cardiac catheterization laboratory, particularly patients with ST-elevation myocardial infarctions (STEMI).</b>  2010 – 2013  Faculty Mentor: Dr. Joseph Thomas, Assistant Professor, Assistant Fellowship Program Director, Harbor-UCLA Medical Center</p> </li> <li> <p><b>Harbor-UCLA, Division of Cardiology: Clinical research involving the utilization of computed tomography in the evaluation of various cardiovascular diseases.</b>  2007 – 2009  Faculty Mentor: Dr. Matthew Budoff, Associate Professor, Fellowship Program Director and Director of Cardiac Computed Tomography, Harbor-UCLA Medical Center</p> </li> <li> <p><b>UCLA Heart Transplant Program: Clinical research involving the medical care of cardiac transplant recipients.</b>  2007 – 2009  Faculty Mentor: Dr. Jon Kobashigawa, Clinical Professor and Medical Director of the UCLA Heart Transplant Program</p> </li> </ul>
<p><b>Publications and Presentations:</b></p>	<p>ARTICLES</p> <ul style="list-style-type: none"> <li> <p>Ahmadi N, Hajsadeghi F, Gul K, Leibfried M, DeMoss D, <b>Lee R</b>, Flores F, Nasir K, Hecht H, Naghavi M, Budoff MJ. Vascular Function Measured by Fingertip Thermal Reactivity is Impaired in Patients with Metabolic Syndrome and Diabetes Mellitus. <i>Journal of Clinical Hypertension</i>, November 2009; 11(11): 678-84.</p> </li> <li> <p>Ibebuaju UN, Nasir K, Gopal A, Ahmadi N, Mao SS, Young E, Honoris L, Nuguri VK, <b>Lee RS</b>, Usman N, Rostami B, Pal R, Flores F, Budoff MJ. Comparison of Atherosclerotic Plaque Burden and Composition Between Diabetic and Non-diabetic Patients by Non-invasive CT Angiography. <i>International Journal of Cardiovascular Imaging</i>, October 2009; 25(7):</p> </li> </ul>

717-23.

- Nagarakanti R, Sodhi S, **Lee R**, Ezekowitz M. Chronic Antithrombotic Therapy in Post- Myocardial Infarction Patients. *Cardiology Clinics, May 2008; 26(2): 277-88.*
- Sodhi S, **Lee R**, Ezekowitz M. Chronic Antithrombotic Therapy in Post- Myocardial Infarction Patients. *Clinics in Geriatric Medicine, February 2006; 22(1): 167-82.*

#### ABSTRACTS

- **RS Lee**, R Kaushal, T Bholat, KA Zhiroff, SC Jaquez, QT Bui, JL Thomas, WJ French. Patient Differences by Mode of Hospital Arrival for ST-Elevation Myocardial Infarction Treated with Primary PCI. *Journal of the American College of Cardiology, November 2011; 58(20): B91.*
- Jug B, Papazian J, **Lee R**, Budoff MJ. Association of Lipoprotein Subfractions and Coronary Calcifications in Individuals at Intermediate Cardiovascular Risk. *Journal of Cardiovascular Computed Tomography, June 2011; 5(4): S16.*
- Hajsadeghi F, Ahmadi N, **Lee R**, Sarlak B, Ramirez J, Flores F, Mao SS, Budoff MJ. Low Density Lipoprotein, High Density Lipoprotein and Lipoprotein (a) Subclasses and Their Relationship With Coronary Artery Calcification Is Asymptomatic Population. *Journal of the American College of Cardiology, March 2008; 51(10): A150.*
- Ibebuogu UN, Nasir K, Gopal A, Ahmadi N, Mao SS, Young E, Honoris L, Nuguri VK, **Lee R**, Usman N, Rostami B, Pal R, Flores F, Budoff M. Comparison of Coronary Atherosclerotic Plaque Burden and Composition Between Diabetic and Nondiabetic Patients by Noninvasive CT Angiography. *Arteriosclerosis, Thrombosis, and Vascular Biology, June 2008; 28(6): e134-e135.*
- **Lee R**, Hajsadeghi F, Ramirez R, Sarlak B, Gopal A, Ahmadi N, Budoff MJ. Insulin Resistance and Coronary Artery Calcification measured by Electron Beam Computed Tomography. *Circulation, October 2007; 116(16): S611.*
- Budoff MJ, **Lee R**, Hajsadeghi F, Ahmadi N, Gopal A, Flores F. Homocysteine, Lipid Parameters, and Inflammatory Markers Relationship to Advanced Coronary Atherosclerosis on CT. *Journal of Cardiovascular Computed Tomography, July 2007; 1(15): S9.*
- Budoff MJ, Gao YL, Child J, Carson S, Liu SL, Young E, **Lee RS**, Zemsky A, Shareghi S, Gopal A, Mao SS. A Comparison of Electron Beam Computed Tomography and 64-Channel Multislice Computed Tomography Scanner in Measuring Coronary Artery Calcium. *Journal of Nuclear Cardiology, April 2007; 14(2): S92.*
- Seto TC, Barrett M, Bradley J, **Lee R**. Mastering Cardiac Auscultation over the Internet: Use of Computer-based Testing to Demonstrate the Power of Repetition. *Chest, October 2004; 126(4): 880-881Sb.*
- **Lee RS**, Devereaux DC, Hamilton MA, Kobashigawa JA. Is Corticosteroid Weaning More Successful in Older Heart Transplant Patients? *Journal of Investigative Medicine, January 2000; 48(1): 3A.*

- Kobashigawa JA, Takemoto S, Wener L, Tobis J, **Lee R**, Kumar N, Chuang JM, Moriguchi JD, Kawata N, Laks H. Development of Circulating, IgG Class I Antibodies is Associated with Increase in Intimal Thickness by Intravascular Ultrasound (IVUS) after Heart Transplant. *The Journal of Heart and Lung Transplantation, January 2000; 19(1): 81-82.*
- Kobashigawa J, Kubak B, Camara R, English J, **Lee R**, Moriguchi J, Hamilton M, Hage A, Kawata N, Laks H. Effective Cytomegalovirus Prophylaxis with Intravenous Followed by Oral Ganciclovir for Donor Positive/Recipient Negative Mismatch. *Transplantation, April 15, 1999; 67(7): S102.*
- **Lee RS**, Ro TK, Hamilton MA, Kobashigawa JA. Treatment of Hypertension in Cardiac Transplant Recipients with Irbesartan. *Journal of Investigative Medicine, February 1999; 47(2): 5A.*
- Kobashigawa JA, Ro TK, Moriguchi JD, **Lee RS**, Cassem JD, Hamilton MA, Hage A, Kawata N, Laks H. Hemodynamic Compromising Rejection is Associated with Increased Incidence of Transplant Coronary Artery Disease in Cardiac Transplant Recipients. *The Journal of Heart and Lung Transplantation, January 1999; 18(1): 50.*
- English JA, Hamilton MA, **Lee RS**, Kobashigawa JA. Effective Cytomegalovirus Prophylaxis with Intravenous Followed by Oral Ganciclovir. *Journal of Investigative Medicine, March 1998; 46(3); 200A.*

#### PRESENTATIONS

- **RS Lee**, R Kaushal, T Bholat, KA Zhiroff, SC Jaquez, QT Bui, JL Thomas, WJ French. Patient Differences by Mode of Hospital Arrival for ST-Elevation Myocardial Infarction Treated with Primary PCI. *Transcatheter Cardiovascular Therapeutics, San Francisco, CA, November 8, 2011.*
- Wallin D, Hunt D, **Lee R**. Adrenal Insufficiency: An Unusual Cause of Hypercalcemia. *Solomon Scholars, University of California at Los Angeles, Los Angeles, CA, June 9, 2009.*
- Yan E, **Lee, R**, Swerdloff R. A Case of Elephantiasic Nodular Pretibial Myxedema? *Solomon Scholars, University of California at Los Angeles, Los Angeles, CA, June 9, 2009.*
- **Lee R**, Hajsadeghi F, Ahmadi N, Gopal A, Flores F, Budoff M. Serum Inflammatory Markers and Coronary Artery Calcification. *Solomon Scholars, University of California at Los Angeles, Los Angeles, CA, June 12, 2007.*
- **Lee RS**, Devereaux DC, Hamilton MA, Kobashigawa JA. Is Corticosteroid Weaning More Successful in Older Heart Transplant Patients? *American Federation for Medical Research, Western Regional Meetings, Carmel, CA, February 9-12, 2000.*
- **Lee RS**, Ro TK, Hamilton MA, Kobashigawa JA. Treatment of Hypertension in Cardiac Transplant Recipients with Irbesartan. *American Federation for Medical Research, Western Regional Meetings, Carmel, CA, January 27-30, 1999.*

<b>Foreign Languages:</b>	<ul style="list-style-type: none"> <li>• Spanish and Korean</li> </ul>
<b>Committees:</b>	<p>HARBOR-UCLA MEDICAL CENTER</p> <ul style="list-style-type: none"> <li>• <b>Ad Hoc Committee for the Internal Review of the Pediatric Neonatal/Perinatal Training Program</b> April 2009</li> <li>• <b>Clinical Radiology Committee</b> 2008 – 2009</li> <li>• <b>Utilization Review Committee</b> 2008 – 2009</li> <li>• <b>Internal Medicine Quality Improvement Committee</b> 2008 – 2009</li> <li>• <b>Intern Selection Committee</b> 2008 – 2009</li> </ul>
<b>Professional Societies:</b>	<ul style="list-style-type: none"> <li>• <b>American Society for Cardiovascular Angiography and Interventions (FSCAI)</b> Member</li> <li>• <b>American College of Cardiology (FACC)</b> Member</li> <li>• <b>American Heart Association (AHA)</b> Member</li> </ul>
<b>Education and Training:</b>	<ul style="list-style-type: none"> <li>• <b>Interventional Cardiology Fellowship</b> <b>Harbor-UCLA Medical Center/Good Samaritan Hospital</b> Torrance, CA/Los Angeles, CA 2012 – 2013</li> <li>• <b>Chief Fellow, General Cardiology</b> <b>Harbor-UCLA Medical Center</b> Torrance, CA 2011 – 2012</li> <li>• <b>General Cardiology Fellowship</b> <b>Harbor-UCLA Medical Center</b> Torrance, CA 2009 – 2012</li> <li>• <b>Chief Resident, Internal Medicine</b> <b>Harbor-UCLA Medical Center</b> Torrance, CA 2008 – 2009</li> </ul>

- **Residency, Internal Medicine**  
**Harbor-UCLA Medical Center**  
Torrance, CA  
2006 – 2008
- **Internship, Internal Medicine**  
**Harbor-UCLA Medical Center**  
Torrance, CA  
2005 – 2006
- **Medical Doctorate (MD)**  
**Drexel University, College of Medicine, Class of 2005**  
Philadelphia, PA  
2001 – 2005
- **Certificate, Interdepartmental Medical Sciences Program**  
**Medical College of Pennsylvania, Hahnemann University**  
Philadelphia, PA  
2000 – 2001
- **Bachelor of Science, Biochemistry**  
**Minor, Applied Developmental Psychology**  
**University of California Los Angeles, Class of 2000**  
Los Angeles, CA  
1995 – 2000